UNSPSC 51124304: Quinidine gluconate

This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.C6H12O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6875N380F, chemically known as quinidine, d-gluconate (salt) but more generally known as quinidine gluconate, which bears US NIH Compound Identifier 64642. European Medicines Agency schedules Quinidine gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04170MIG.

UNSPSC 51124304 Quinidine gluconate, a Commodity code, encompasses pharmaceutical active ingredients and finished-form medications procured by state and local health agencies, emergency medical services, and public health programs. Recent solicitations show state and local governments buying advanced life support medications, generic pharmaceuticals, and over-the-counter products through direct vendor procurement, cooperative purchasing agreements, and manufacturer-to-wholesaler supply chains. The City of Tampa's fire rescue department, state health and human services commissions, and multistate cooperative purchasing alliances are primary issuing bodies under this code, with procurement ranging from small sealed-bid purchases of specific medication line items to large-scale RFPs establishing statewide or multi-state supplier agreements.

Activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (response due April 8, 2026) seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with nine-month minimum expiration dates and one-year contract term plus renewal options, with an estimated contract value of $40,000.00 and a 5 percent small local business enterprise bid discount available. The Texas Health and Human Services Commission posted RFI HHS0017013 (response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct state relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors required to maintain relationships with authorized wholesalers (AmerisourceBergen Cencora, Cardinal Health, and Morris & Dickson) and meet June Manufacturing Practices and Drug Supply Chain Security Act compliance.